Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -2158.37% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-2158.37%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$6.57B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.50B
EBITDA Margin
24.71%
TTM Avg
29.36%
3Y Avg
25.12%
5Y Avg
17.03%
Market Cap
$6.49B
EBITDA Margin
21.42%
TTM Avg
19.40%
3Y Avg
15.87%
5Y Avg
16.39%
Market Cap
$6.66B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$6.25B
EBITDA Margin
-100.49%
TTM Avg
-151.66%
3Y Avg
-322.50%
5Y Avg
-1329.03%
Market Cap
$6.02B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.94B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.55B | -2158.37% | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | 6.82% | 6.08% | -0.44% | -8.67% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 24.71% | 29.36% | 25.12% | 17.03% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 21.42% | 19.40% | 15.87% | 16.39% |
| Chemed Corporation (CHE)vs › | $6.66B | 15.93% | 16.80% | 17.55% | 18.41% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | -100.49% | -151.66% | -322.50% | -1329.03% |
| Alkermes plc (ALKS)vs › | $6.99B | 19.05% | 23.95% | 20.94% | 15.97% |
| GRAIL Inc. (GRAL)vs › | $6.02B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 30.20% | 18.88% | 24.58% | 33.74% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | -139.44% | -176.89% | -12100.88% | -12100.88% |
Gross Margin
0.0%
EBITDA Margin
-2158.4%
Operating Margin
0.0%
Net Margin
-7585.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2158.37% |
